[
  {
    "ts": "2026-02-01T05:07:00+00:00",
    "headline": "Johnson & Johnson’s Myeloma Approval And What It May Mean For JNJ Stock",
    "summary": "Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This decision expands treatment options for a specific group of multiple myeloma patients. For Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex...",
    "url": "https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9f705bca-74dd-3f1f-9d37-45287d24ac11",
      "content": {
        "id": "9f705bca-74dd-3f1f-9d37-45287d24ac11",
        "contentType": "STORY",
        "title": "Johnson & Johnson’s Myeloma Approval And What It May Mean For JNJ Stock",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This decision expands treatment options for a specific group of multiple myeloma patients. For Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex...",
        "pubDate": "2026-02-01T05:07:00Z",
        "displayTime": "2026-02-01T05:07:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-myeloma-approval-may-050700975.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]